Biodexa Secures Syngene Partnership for MTX240 Clinical Trial Manufacturing
summarizeSummary
Biodexa Pharmaceuticals has announced a partnership with Syngene International for the manufacturing of MTX240 active pharmaceutical ingredient and dosage form, which will supply GMP clinical trial supplies. This agreement is a critical operational step in advancing MTX240, a molecular glue technology for Gastrointestinal Stromal Tumors (GIST), towards its planned Phase 1b/2a study later this year. The partnership demonstrates continued execution on a key pipeline asset, especially following the recent licensing of MTX240 from Otsuka in February. This development provides a positive operational update for the micro-cap company, which recently reported a significant net loss and "substantial doubt" about its ability to continue as a going concern, indicating ongoing progress despite financial challenges.
في وقت هذا الإعلان، كان BDRX يتداول عند ٠٫٦٦ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ١٫٤ مليون US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ٠٫٦٠ US$ و١٩٫٣٠ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية إيجابية وبدرجة أهمية ٧ من 10. المصدر: GlobeNewswire.